Inflammasome as an Effective Platform for Fibrosis Therapy

Ting-Ting Chen,* Feng Xiao,* Nan Li, Shan Shan, Meng Qi, Zi-Ying Wang, Sheng-Nan Zhang, Wei Wei, Wu-Yi Sun Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Infla...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen TT, Xiao F, Li N, Shan S, Qi M, Wang ZY, Zhang SN, Wei W, Sun WY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	inflammasome fibrosis nlrp3 aim2 caspase-1 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/73701db02df34806b78cbf24cf2b2822
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73701db02df34806b78cbf24cf2b2822
record_format	dspace
spelling	oai:doaj.org-article:73701db02df34806b78cbf24cf2b28222021-12-02T14:28:08ZInflammasome as an Effective Platform for Fibrosis Therapy1178-7031https://doaj.org/article/73701db02df34806b78cbf24cf2b28222021-04-01T00:00:00Zhttps://www.dovepress.com/inflammasome-as-an-effective-platform-for-fibrosis-therapy-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Ting-Ting Chen,* Feng Xiao,* Nan Li, Shan Shan, Meng Qi, Zi-Ying Wang, Sheng-Nan Zhang, Wei Wei, Wu-Yi Sun Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Hefei, Anhui Province, 230032, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wu-Yi Sun; Wei WeiInstitute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, 81 Meishan Road, Hefei, Anhui Province, 230032, People’s Republic of ChinaTel/Fax +86 551 65161209Email sunwuyi51@aliyun.com; wwei@ahmu.edu.cnAbstract: Fibrosis is the final stage of the development of chronic inflammation. It is characterized by excessive deposition of the extracellular matrix, leading to tissue structure damage and organ dysfunction, which is a serious threat to human health and life. However, the molecular mechanism of fibrosis is still unclear. Inflammasome is a molecular complex of proteins that has been becoming a key innate sensor for host immunity and is involved in pyroptosis, pathogen infection, metabolic syndrome, cellular stress, and tumor metastasis. Inflammasome signaling and downstream cytokine responses mediated by the inflammasome have been found to play an important role in fibrosis. The inflammasome regulates the secretion of IL-1β and IL-18, which are both critical for the process of fibrosis. Recently, researches on the function of inflammasome have attracted extensive attention, and data derived from these researches have increased our understanding of the effects and regulation of inflammasome during fibrosis. In this review, we emphasize the growing evidence for both indirect and direct effects of inflammasomes in triggering fibrosis as well as potential novel targets for antifibrotic therapies.Keywords: inflammasome, fibrosis, NLRP3, AIM2, caspase-1Chen TTXiao FLi NShan SQi MWang ZYZhang SNWei WSun WYDove Medical Pressarticleinflammasomefibrosisnlrp3aim2caspase-1PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 1575-1590 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	inflammasome fibrosis nlrp3 aim2 caspase-1 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	inflammasome fibrosis nlrp3 aim2 caspase-1 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Chen TT Xiao F Li N Shan S Qi M Wang ZY Zhang SN Wei W Sun WY Inflammasome as an Effective Platform for Fibrosis Therapy
description	Ting-Ting Chen,* Feng Xiao,* Nan Li, Shan Shan, Meng Qi, Zi-Ying Wang, Sheng-Nan Zhang, Wei Wei, Wu-Yi Sun Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Hefei, Anhui Province, 230032, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wu-Yi Sun; Wei WeiInstitute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, 81 Meishan Road, Hefei, Anhui Province, 230032, People’s Republic of ChinaTel/Fax +86 551 65161209Email sunwuyi51@aliyun.com; wwei@ahmu.edu.cnAbstract: Fibrosis is the final stage of the development of chronic inflammation. It is characterized by excessive deposition of the extracellular matrix, leading to tissue structure damage and organ dysfunction, which is a serious threat to human health and life. However, the molecular mechanism of fibrosis is still unclear. Inflammasome is a molecular complex of proteins that has been becoming a key innate sensor for host immunity and is involved in pyroptosis, pathogen infection, metabolic syndrome, cellular stress, and tumor metastasis. Inflammasome signaling and downstream cytokine responses mediated by the inflammasome have been found to play an important role in fibrosis. The inflammasome regulates the secretion of IL-1β and IL-18, which are both critical for the process of fibrosis. Recently, researches on the function of inflammasome have attracted extensive attention, and data derived from these researches have increased our understanding of the effects and regulation of inflammasome during fibrosis. In this review, we emphasize the growing evidence for both indirect and direct effects of inflammasomes in triggering fibrosis as well as potential novel targets for antifibrotic therapies.Keywords: inflammasome, fibrosis, NLRP3, AIM2, caspase-1
format	article
author	Chen TT Xiao F Li N Shan S Qi M Wang ZY Zhang SN Wei W Sun WY
author_facet	Chen TT Xiao F Li N Shan S Qi M Wang ZY Zhang SN Wei W Sun WY
author_sort	Chen TT
title	Inflammasome as an Effective Platform for Fibrosis Therapy
title_short	Inflammasome as an Effective Platform for Fibrosis Therapy
title_full	Inflammasome as an Effective Platform for Fibrosis Therapy
title_fullStr	Inflammasome as an Effective Platform for Fibrosis Therapy
title_full_unstemmed	Inflammasome as an Effective Platform for Fibrosis Therapy
title_sort	inflammasome as an effective platform for fibrosis therapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/73701db02df34806b78cbf24cf2b2822
work_keys_str_mv	AT chentt inflammasomeasaneffectiveplatformforfibrosistherapy AT xiaof inflammasomeasaneffectiveplatformforfibrosistherapy AT lin inflammasomeasaneffectiveplatformforfibrosistherapy AT shans inflammasomeasaneffectiveplatformforfibrosistherapy AT qim inflammasomeasaneffectiveplatformforfibrosistherapy AT wangzy inflammasomeasaneffectiveplatformforfibrosistherapy AT zhangsn inflammasomeasaneffectiveplatformforfibrosistherapy AT weiw inflammasomeasaneffectiveplatformforfibrosistherapy AT sunwy inflammasomeasaneffectiveplatformforfibrosistherapy
_version_	1718391259461058560

Inflammasome as an Effective Platform for Fibrosis Therapy

Ejemplares similares